MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis

10 May 2025 06:15:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates

01 May 2025 06:00:01 By Nasdaq GlobeNewswire

Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress

29 Apr 2025 07:00:01 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025

18 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer

16 Apr 2025 06:00:00 By Nasdaq GlobeNewswire

Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors

11 Mar 2025 07:00:01 By Nasdaq GlobeNewswire

NetDania - New 12 months High: MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

26 Feb 2025 11:00:56 By NetDania Notify

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

26 Feb 2025 06:00:00 By Nasdaq GlobeNewswire

Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

26 Feb 2025 05:30:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

21 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

12 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

13 Jan 2025 05:45:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

03 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

07 Nov 2024 10:24:15 By NetDania Notify

NetDania - New 12 months High: MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

06 Nov 2024 08:45:20 By NetDania Notify

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

06 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

05 Nov 2024 15:15:01 By NetDania Notify

NetDania - New 12 months High: MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

04 Nov 2024 08:47:38 By NetDania Notify

NetDania - New 12 months High: MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

01 Nov 2024 09:37:32 By NetDania Notify

Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates

31 Oct 2024 06:00:01 By Nasdaq GlobeNewswire